Lucid Diagnostics appoints Debra J. White as Class C director effective August 1, 2022

Lucid Diagnostics Inc.

Debra J. White appointed to Board, replacing Aster Angagaw who resigned July 30; resignation not due to disagreement.
White received option to purchase 80,000 shares at $2.95/share, vesting in 12 quarterly installments starting Sept 30, 2022.
White also serves on board of parent PAVmed Inc.; joins nominating/corporate governance and audit committees.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Debra J. White

Class C director

LUCD · Lucid Diagnostics Inc.

Effective: 2022-08-01
Filed: August 2, 2022, 7:59 PM ET

appointed Debra J. White as a Class C director of the Company.

Departed

Aster Angagaw

director

LUCD · Lucid Diagnostics Inc.

Effective: 2022-07-30
Successor: Debra J. White
Filed: August 2, 2022, 7:59 PM ET

Ms. White replaces Aster Angagaw, who resigned as a director effective on July 30, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Debra J. White was appointed as Class C director at Lucid Diagnostics Inc..

Action: appointed
Role: Class C director

Exact text from the filing

appointed Debra J. White as a Class C director of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Aster Angagaw resigned as director at Lucid Diagnostics Inc..

Action: resigned
Role: director

Exact text from the filing

Ms. White replaces Aster Angagaw, who resigned as a director effective on July 30, 2022.

View on SEC.gov

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-021012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.